Merit Medical Systems Reports 12-14% Increase in Q2 2025 Revenue, Reaching $380-$384 Million

Reuters
12 Jul
<a href="https://laohu8.com/S/MMSI">Merit Medical Systems</a> Reports 12-14% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue, Reaching $380-$384 Million

Merit Medical Systems Inc. has announced its preliminary unaudited revenue for the second quarter of 2025, reporting a range of approximately $380 to $384 million. This reflects a projected increase of approximately 12% to 14% compared to the revenue reported for the same quarter in 2024. Additionally, the preliminary constant currency revenue for the quarter increased by approximately 11% to 13% compared to the prior year period. The company plans to release its full financial results for the quarter ended June 30, 2025, on July 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000856982-25-000041), on July 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10